# US 2026/0091010 A1 · Compositions and methods for managing rebound of body weight and metabolic parameters

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091010 A1
- Document ID: US20260091010A1
- Status: Published application
- Kind: A1
- Application number: 19/346,447
- Filed: 2025-09-30
- Published: 2026-04-02
- Earliest claimed: 2024-09-30
- Assignees: EFIL BioScience Inc.
- Applicants: Efil Bioscience Inc.
- Inventors: Jeong-Hoon KIM; Mu Lim CHOI; Kee-Hong KIM
- Web page: https://patentgrep.com/patent/US20260091010A1

## CPC

- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 38/26: Glucagons
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions comprising one or more ACAT inhibitors and one or more GLP-1 receptor agonists (GLP-1 RAs). The combination therapy reduces side effects associated with high-dose GLP-1 RA monotherapy and provides durable management of weight loss by suppressing rebound of body weight, blood glucose, and cholesterol levels after treatment.

## Claims

### Claim 1

A method for managing body weight and metabolic parameters in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a combination of one or more GLP-1 receptor agonists (GLP-1 RAs) and one or more ACAT inhibitors, wherein the combination therapy is effective to achieve one or more of the following:
a. delaying and reducing weight regain after cessation of the treatment compared to GLP-1 RA monotherapy;
b. minimizing or suppressing the rebound in blood cholesterol levels after cessation of the treatment compared to GLP-1 RA monotherapy; and
c. minimizing or suppressing the rebound in blood glucose levels after cessation of the treatment compared to GLP-1 RA monotherapy.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said GLP-1 RA is selected from the group consisting of lixisenatide, liraglutide, exenatide, albiglutide, semaglutide, dulaglutide, tirzepatide, retatrutide, orforglipron, lotiglipron, efpeglenatide, and taspoglutide.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said ACAT inhibitor is selected from the group consisting of avasimibe, CI-976, eflucimibe, and a pharmaceutically acceptable salt, derivative, or analog thereof.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said GLP-1 RA and said ACAT inhibitor are formed in a single formulation and the formulation is administered.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said GLP-1 RA and said ACAT inhibitor are formulated separately and administered simultaneously or sequentially.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said GLP-1 RA is liraglutide, semaglutide, or tirzepatide, and said ACAT inhibitor is avasimibe (CI-1011), K-604, CI-976, eflucimibe (F12511), or a pharmaceutically acceptable salt, derivative, or analog thereof.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the combination therapy is effective to further achieve one or more of the following:
a. enabling the use of a lower dose of GLP-1 RA compared to GLP-1 RA monotherapy; and
b. reducing or preventing muscle loss during the treatment period or the post-treatment period compared to GLP-1 RA monotherapy.

### Claim 8

A pharmaceutical composition for managing body weight and metabolic parameters in a subject in need thereof, the composition comprising one or more GLP-1 receptor agonists (GLP-1 RAs) and one or more ACAT inhibitors, wherein the composition is formulated to achieve one or more of the following:
a. delaying or reducing weight regain after cessation of the treatment compared to GLP-1 RA monotherapy;
b. minimizing or suppressing the rebound in blood cholesterol levels after cessation of the treatment compared to GLP-1 RA monotherapy; and
c. minimizing or suppressing the rebound in blood glucose levels after cessation of the treatment compared to GLP-1 RA monotherapy.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein said GLP-1 RA is selected from the group consisting of lixisenatide, liraglutide, exenatide, exenatide extended release, albiglutide, semaglutide, ITCA 650, dulaglutide, tirzepatide, retatrutide, orforglipron, lotiglipron, efpeglenatide, and taspoglutide.

### Claim 10 (depends on 8)

The pharmaceutical composition according to claim 8, wherein said ACAT inhibitor is selected from the group consisting of avasimibe, CI-976, eflucimibe, and a pharmaceutically acceptable salt, derivative, or analog thereof.

### Claim 11 (depends on 8)

The pharmaceutical composition according to claim 8, wherein said GLP-1 RA is liraglutide, semaglutide, or tirzepatide, and said ACAT inhibitor is avasimibe (CI-1011), K-604, CI-976, eflucimibe (F12511), or a pharmaceutically acceptable salt, derivative, or analog thereof.

### Claim 12 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the composition is formulated to achieve one or more of the following:
a. enabling the use of a lower dose of GLP-1 RA compared to GLP-1 RA monotherapy; and
b. reducing or preventing muscle loss during the treatment period or the post-treatment period compared to GLP-1 RA monotherapy.
